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OBJECTIVEdTo investigate temporal improvements in blood pressure (BP) control in sub-
jects with diabetes and policy changes regarding generic antihypertensives.
RESEARCH DESIGN AND METHODSdIn a cross-sectional study we used logistic
regression models to investigate the temporal relationship between access to generic antihyper-
tensive medications and BP control (,130/80mmHg) in 5,375 subjects (mean age, 666 9 years;
61% African American) with diabetes and hypertension (HTN) enrolled in the national Results
from the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study
between 2003 and 2007. At enrollment, BP was measured and medications in the home
determined by medication label review by a trained professional. Generic antihypertensive
medication status was ascertained from the U.S. Food and Drug Administration.
RESULTSdThe percentage of subjects accessing generically available antihypertensive med-
ications increased signiﬁcantly from 66% in 2003 to 81% in 2007 (P, 0.0001), and the odds of
achieving a BP,130/80 mmHg in 2007 was 66% higher (odds ratio 1.66 [95% CI 1.30–2.10])
than in 2003.Nevertheless,,50%of participants achieved this goal. African American race,male
sex, limited income, and medication nonadherence were signiﬁcant predictors of inadequate BP
control. There was no signiﬁcant relationship between access to generic antihypertensives and BP
control when other demographic factors were included in the model (0.98 [0.96–1.00]).
CONCLUSIONSdAmong African American and white subjects with HTN and diabetes, BP
control remained inadequate relative to published guidelines, and racial disparities persisted.
Although access to generic antihypertensives increased, this was not independently associated
with improved BP control, suggesting that poor BP control is multifactorial.
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A lthough recent controversy existsregarding the optimal target bloodpressure (BP) value (1), it remains
clear that consistent control of BP in
patients with diabetes is important for
limiting microvascular and macrovascu-
lar complications (2,3). However, our
data (4) and other recent evidence (5)
suggests that half or more of individuals
with diabetes and hypertension are not
meeting currently published target BP val-
ues (,130/80 mmHg), and we and others
(4–6) have shown that racial disparities in
BP control persist. Inadequate control is
clearly multifactorial in origin (7), but evi-
dence suggests that African Americanswith
hypertension are prescribed more antihy-
pertensive agents, presumably to improve
control and limit this disparity (6).
Our group (4) and Wang (8) have
demonstrated a modest temporal im-
provement in BP control among diabetic
subjects during recent years (2000–
2007). We (4) have shown that this pat-
tern of improvement was evident in both
African American and white individuals.
Although some data (9) suggest that this
improvement results from longitudinal
effects of the promulgation of the 2003
Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of
High Blood Pressure guidelines (10),
other factors may also be operative. Sev-
eral temporal factors may be associated
with improvement in BP control. In
2006, the introduction of both Medicare
Part D drug coverage and inexpensive ge-
neric drug formularies (e.g., pharmacies
at Wal-Mart) provided the potential for
improved cost-related medication adher-
ence. Another factor may be access to ad-
ditional effective antihypertensive agents.
Recent evidence from Briesacher et al.
(11) has shown in adjusted models that
the use of generic medications among di-
abetic patients can lead to modest but sig-
niﬁcant improvements in medication
adherence. However, their study used
employer-sponsored medical claims data
to assess individuals beginning new drug
therapy for chronic conditions, thus lim-
iting the study’s generalizability. There-
fore, we explored the relationship between
increased access to genericmedications and
patterns of BP control in a population-
based sample. We evaluated secular trends
in access to generic antihypertensive drugs
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in hypertensive diabetic subjects from
2003 through 2007. In addition, we deter-
mined if there were discernible differences
in these trends by race and whether this
access to generic antihypertensives was as-
sociated with improved BP control.
RESEARCH DESIGN AND
METHODSdThe REasons for Geo-
graphic And Racial Disparities in Stroke
(REGARDS) study is a study of health
disparities and stroke incidence, the
methods of which have been described
in detail elsewhere (12). In short,
REGARDS is a population-based, longitu-
dinal cohort study of 30,239 subjects
aged $45 years; 45% are men and 55%
are women; 41% are African American
and 59% are white; and 55% are from
the “Stroke Belt” region (southeastern U.S.)
and 45% are from the rest of the continental
U.S. The REGARDS study is designed to
examine thepotential causes of excess stroke
mortality in the Stroke Belt relative to the
rest of the nation and among African
Americans relative to whites. REGARDS
provides a unique opportunity to examine
recent trends in access to generic medica-
tions and BP control among African Ameri-
can and white hypertensive adults with
diabetes. The study is national in scope
and includes large numbers of adults with
diabetes and hypertension.
The REGARDS cohort was recruited
between January 2003 and October 2007.
Enrollment of the cohort occurred during
the implementation ofMedicare Part D and
generic formulary systems (e.g., pharma-
cies at Wal-Mart). REGARDS included a
detailed computer-assisted telephone in-
terview with each subject to collect de-
mographic characteristics, including age,
race (each subject self-reported race and, by
design, Hispanic and Latino subjects were
excluded; the REGARDS study compared
only non-Hispanic African American and
white subjects), and sex. Additional data
collected through this interview included
the following: annual household income
(,$20,000, $20,000–$34,000, $35,000–
$74,000, and $$75,000); education level
(less than high school education, high
school graduate, some college, and college
graduate or higher); health insurance (yes
or no); and health behaviors. Health behav-
ior data included smoking (categorized as
nonsmoker, past smoker, or current
smoker); exercise (how often per week
the subject exercised enough to work
up a sweat, categorized as never, one to
three times per week, or four or more
times per week); alcohol consumption
(categorized as none, moderate [one to
seven drinks per week for women and
one to 14 drinks per week for men], and
heavy [anything more than moderate alco-
hol consumption]), and medical history
information.
After the telephone interview, each
subject completed an in-home visit con-
ducted by a trained health professional,
which included measurement of height
and weight via standard procedures. BMI
was calculated as the weight in kilograms
divided by the height in meters squared.
BP was obtained with an aneroid sphyg-
momanometer, using the appropriate cuff
size, and was measured after the subject
had been seated with both feet on the ﬂoor
for at least 3 min. The average value of two
BP measurements was used in analyses. At
the home visit, blood specimens were
obtained and total and HDL cholesterol lev-
els were measured in accordance with the
National Cholesterol Education Program
guidelines (13). All prescription medication
names were recorded verbatim from the
pharmacy label during the home visit.
Self-reportedmedication adherence or non-
adherencewas assessedusing thepreviously
validated four-itemMorisky scale (14). This
cross-sectional study of baseline data at the
time of enrollment included all subjects
who reported in their telephone interview
that a physician had told them they had
both hypertension/high blood pressure
and diabetes. No in-home blood pressure
or blood glucose measurements were used
as a diagnostic measure for inclusion. Ex-
cluded from these analyses were any sub-
jects who did not have both systolic BP and
diastolic BP measurements (n = 22). The
study was approved by the Institutional Re-
view Board at the University of Alabama-
Birmingham, and each subject provided
informed consent.
The primary exposure was the per-
centage of antihypertensive medications
Table 1dDemographic and cardiovascular risk characteristics by race of the REGARDS
study population with self-reported hypertension and diabetes (N = 5,375)
Characteristics
White
(n = 2,116)
African American
(n = 3,259) P*
Mean age (years 6 SD) 66.6 6 8.5 65.1 6 8.6 ,0.0001
Female sex 44.7 63.0 ,0.0001
Stroke Belt resident 64.0 54.5 ,0.0001
Education
Less than high school 11.6 26.9 ,0.0001
High school graduate 28.8 29.1
Some college 29.6 23.9
College graduate 30.0 20.2
Health insurance 95.6 91.1 ,0.0001
Annual household income ($)
,20,000 19.1 32.4 ,0.0001
20,000–34,000 26.8 27.4
35,000–74,000 31.3 19.6
$75,000 12.2 5.8
Refused to respond 10.6 14.7
Subjects taking antihypertensive
medications and reporting any nonadherence 22.9 23.3 0.79
Current smoker 11.9 15.3 ,0.0001
Weekly exercise
None 43.0 43.0 ,0.0005
1–3 times 30.6 34.7
$4 times 26.4 22.3
Alcohol use
None 70.4 78.8 ,0.0001
Moderate 27.0 19.9
Heavy 2.6 1.3
BMI, kg/m2 (mean 6 SD) 32.0 6 6.4 32.8 6 6.8 ,0.0001
Total cholesterol, mg/dL (mean 6 SD) 176.1 6 41.2 181.4 6 42.4 ,0.0001
HDL cholesterol, mg/dL (mean 6 SD) 43.3 6 13.0 50.0 6 14.7 ,0.0001
Data shown as percentages unless otherwise indicated. *P value according to t test for continuous variables or
x2 test for categorical variables.
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belonging to the participant at the time of
their in-home visit that were available on
the market as a generic medication. For
each participant, the percentage of gener-
ically available antihypertensive medica-
tions was determined as the number of
antihypertensive medications being taken
that was generically available at the time
of the in-home visit divided by the total
number of antihypertensive medications
being taken by the participant. The ge-
neric status of each antihypertensivemed-
ication was determined from the U.S.
Food and Drug Administration (FDA)
website (www.fda.gov) by identifying
the approval date for the marketing of
one or more generic products containing
that speciﬁc antihypertensive medication
or combination of medications. The date
of generic medication approval on the
FDA website then was compared with the
date of the REGARDS-related in-home visit
to determine if the antihypertensive medi-
cation was generically available at the time
of the in-home visit. Each antihyper-
tensive medication was also categorized
by pharmacological class (ACE inhibitors,
angiotensin receptor blockers [ARBs],
a-blocker, b-blocker, calcium channel
blocker, central a-agonist, diuretic, vasodi-
lator), and the number of agents from dif-
ferent classes was computed.
The initial analysis estimated the pat-
tern of access to generic antihypertensive
medications over the 2003–2007 time pe-
riod by graphically portraying the per-
centage of all antihypertensives in use
that were generically available during
each year of enrollment.We then assessed
the relationship between the percentage
of generic antihypertensive medications
available and both mean systolic and di-
astolic BP values (obtained during the in-
home visit) as well as the percentage of
subjects meeting American Diabetes As-
sociation (ADA) guideline-recommended
BP goals (,130/80 mmHg). Temporal
trends in the potential relationship be-
tween BP level and both number of anti-
hypertensive medications and percentage
that were available as generics over the
time period 2003–2007 was assessed
using a general linear model, with adjust-
ment for age, sex, race, income, education,
insurance, and medication adherence. The
percentage of hypertensive diabetic subjects
whose BP was ,130/80 mmHg also was
examined in a series of logistic regression
models, stratiﬁed by race, that adjusted for
the same factors. All analyses were per-
formed using SAS version 9 (SAS Inc,
Cary, NC).
RESULTSdData were available for
5,375 subjects who reported having hy-
pertension and diabetes; baseline data by
race are presented in Table 1. Sixty-one
percent of subjects with diabetes and hy-
pertension were African American. As
shown in Table 2, mean systolic and di-
astolic BP values were higher among Afri-
can Americans than whites in each year.
Likewise, the percentage of African Amer-
ican subjects receiving one or more anti-
hypertensive medications was slightly
higher, and the percentage using four or
more antihypertensive medications was
notably higher than that of whites at
each time point. From 2003 to 2007,
the use of ACE inhibitors seemed to
decrease modestly without a discernible
pattern by race. There was also a small
increase in ARB use, again without a dis-
cernible pattern by race. There was a no-
table racial difference in the use of
centrally acting a-agonists (e.g., cloni-
dine), with African Americans being pre-
scribed these agents more than twice as
often as whites in most years.
Twenty-three percent of subjects re-
ported medication nonadherence. Al-
though a contributor to BP control, the
percentage of subjects reportingmedication
nonadherence did not vary signiﬁcantly
across the time period (see Table 2). How-
ever, as shown in Table 2, self-reported
medication nonadherence was higher
among African Americans enrolled in
2003, approximately equal by race in
2004, and then was higher in whites than
African Americans enrolled in 2005–2007.
As shown in Fig. 1, the percentage of
antihypertensive medications that were
available as a generic medication in-
creased signiﬁcantly from 2003 to 2007
(P for trend , 0.001). The highest per-
centage of antihypertensive medications
available as generic medications in 2007
was observed in subjects taking three or
more antihypertensive medications. Dur-
ing this same time period, mean systolic
BP and the odds ratio of subjects meeting
ADA guideline-recommended target BP
values (,130/80 mmHg) improved (P
for trend, 0.001). The results of the gen-
eral linear model predicting systolic BP
demonstrate that multiple factors, includ-
ing younger age, race (African American),
sex (male), and self-reported medication
nonadherence, were independently asso-
ciated with higher systolic BP values (P,
0.05). However, the percentage of medi-
cations available generically was not sig-
niﬁcantly associated with systolic BP
values (P . 0.05). In the logistic regres-
sion model examining the percentage of
subjects with a BP,130/80 mmHg, Afri-
can American race, male sex, annual in-
come ,$35,000, and medication
nonadherence among those with an an-
nual income ,$35,000 were signiﬁcant
(P , 0.05) predictors of inadequate BP
control (see Table 3). The percentage of
antihypertensive medication available in
generic form was not an independent pre-
dictor of BP control after adjustment for
these factors. Residence in the southeastern
U.S. (the Stroke Belt) was also not an in-
dependent predictor of inadequate BP con-
trol. When separate logistic regression
models were examined for each race, after
adjustment for other factors in the model,
Figure 1dPercentage of antihypertensive medications available in a generic form by number of
antihypertensive classes, 2003–2007. Data are least squared mean values adjusted for region (P
value for trend , 0.0001).
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neither the percentage of antihypertensive
medications available in generic form nor
the number of antihypertensive classes be-
ing taken was an independent predictor of
BP control.
CONCLUSIONSdNonadherence to
antihypertensive medications is associated
with poor BP control among patients with
diabetes, and cost-related nonadherence
is a major contributor (15,16). Although
national efforts to improve outcomes is fo-
cused on the dissemination of evidence-
based guidelines (8,10) and public funding
for prescription costs (17), little is known
about the impact of these strategies. This
article adds to the literature by demonstrat-
ing important temporal trends in the equal-
ity of diabetes care. Those trends include a
lower mean systolic BP, improvement in
the percentage of subjects whose BP is at
or below ADA guideline-recommended
goals, and an increase in access to generic
antihypertensivemedications from2003 to
2007 among those with concurrent diabe-
tes andhypertension.However, despite im-
proving BP values and increasing access to
generic antihypertensive medications, the
percentage of antihypertensivemedications
that are available in a generic form is not
independently associated with improved
BP control in multivariable analysis after
adjustment for demographic and clinical
variables. This ﬁnding is contrary to our
hypothesis of an association between in-
creased access to generic antihypertensives
and improved BP control. Access to generic
medication is only one of the factors inﬂu-
encing behavior with taking antihyperten-
sive medication and BP control, and other
unmeasured factors that impact both be-
havior with taking medication and BP con-
trol may be operative. These factors may
include the patient’s perceptions regarding
the severity of illness and the necessity of
taking the medication, the patient’s trust in
the prescriber, the patient’s health literacy
and comprehension of instructions about
medication use, and the patient’s percep-
tion of harms or risks associated with tak-
ing antihypertensive medications (18).
These ﬁndings have policy implica-
tions related to the limited impact on BP
control that may result from improved
access to generically available antihyper-
tensive medications. Although generic
antihypertensive use should continue be-
cause of the reduced health care costs, it
should not be assumed that simply re-
ducing medication costs alone will insure
medication adherence and improved BP
control. Broader strategies to seek an un-
derstanding of adherence to medication
regimens as a behavior shaped by the be-
liefs and perceptions of the patient may be
needed to affect adherence. Insurance and
health systems that can provide informa-
tion to the provider from pharmacy
claims databases regarding the ﬁlling/re-
ﬁlling of generic antihypertensives may
inform the provider’s ability to provide
tailored health coaching regarding adher-
ence and BP control. Finally, increased
availability of cost-effective generic anti-
hypertensive drugs in multiple pharma-
cologic classes should also facilitate
intensiﬁcation of treatment by the pro-
vider in the setting of uncontrolled BP.
These ﬁndings support the work of
other investigators. The growth in access
to generic medications is well described,
and a recent systematic review (19) sug-
gests comparable clinical outcomes with
brand name and generic antihypertensive
drugs. The growth in generic prescribing
and the potential inﬂuence of electronic
prescribing systems have been demon-
strated by Stenner et al. (20). Van Wijk
et al. (21) has shown that generic drug
substitution among subjects with hyper-
tension leads to a lower rate of nonadher-
ence; however, they have not examined
Table 3dLogistic regression model predicting odds of BP control (<130/80 mmHg) among
hypertensive diabetic subjects (n = 3,485)
OR (95% CI)
Race
White Reference
African American 0.61 (0.52–0.71)
Sex
Men Reference
Women 1.53 (1.30–1.80)
Age (10-year difference) 1.04 (0.94–1.14)
Year
2003 Reference
2004 1.06 (0.87–1.30)
2005 1.42 (1.08–1.87)
2006 1.23 (0.97–1.55)
2007 1.66 (1.30–2.10)
Region
Continental U.S. not including southeast Reference
Stroke Belt 1.03 (0.89–1.20)
BMI 0.97 (0.96–0.98)
Weekly exercise
None Reference
1–3 times 0.90 (0.76–1.07)
$4 times 1.01 (0.85–1.22)
Annual income ($)
,20,000 Reference
20,000–34,000 0.97 (0.79–1.19)
$35,000 1.35 (1.08–1.69)
Education
Less than high school Reference
High school graduate 1.21 (0.98–1.51)
Some college 1.22 (0.97–1.53)
College graduate 1.09 (0.85–1.40)
Insurance 1.19 (0.87–1.62)
Yes Reference
No 1.19 (0.87–1.62)
Medication adherence
Yes Reference
Nonadherence (,$35,000 annual income) 0.78 (0.62–0.99)
Nonadherence ($$35,000 annual income) 0.99 (0.74–1.33)
Antihypertensive medication classes, n 0.96 (0.90–1.03)
Antihypertensive medications available as generic (0.1 difference) (%) 0.98 (0.96–1.00)
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the effect on BP control. The present anal-
ysis demonstrates a temporal pattern of
increased access to generically available
antihypertensive medications that is par-
alleled by improvement in both mean BP
values and the percentage of hypertensive
subjects with diabetes and controlled BP.
Furthermore, in subjects with a limited
income, we show that medication nonad-
herence is a signiﬁcant contributor that
limits the percentage of subjects achieving
ADA guideline-recommended BP control.
It is perhaps reassuring to note that the
percentage of subjects reporting medica-
tion nonadherence changed little across
the time period studied despite increasing
access to generic antihypertensive medi-
cations. This suggests trust in a comparable
level of efﬁcacy from generic medications
relative to brand name medications. As re-
ported above, there is an interesting trend
by race: self-reported medication nonad-
herence was higher in African Americans
enrolled in 2003 but higher in whites en-
rolled in 2005–2007.
It is possible that cost-related non-
adherence may have been higher in Afri-
can Americans with a limited income than
whites in 2003 and may have been af-
fected in later years by the increase in the
availability of generic forms of antihyper-
tensive medications. This ﬁnding war-
rants further investigation.
As we have reported previously (4),
disparities in BP control between African
Americans and whites with diabetes con-
tinue to persist. Our ﬁnding that African
American men in particular have inade-
quate BP control despite improved access
to generic medications suggests that addi-
tional research needs to focus on this
high-risk subgroup. Additional research
is necessary to clearly understand the rel-
evance of generic medications and other
factors that may be associated with BP
control. Subsequently, culturally tailored
interventions designed to speciﬁcally im-
pact these contemporary factors affecting
BP control among African American men
with hypertension and diabetes might be
developed and evaluated.
This study has important limitations.
The examination of temporal trends is
based on cross-sectional data collected
during enrollment visits that occur across
this time period and are examined by year
of enrollment. The study examines BP
control among African American and
white adults$45 years of age, and results
cannot be extrapolated to other racial
groups or younger adults. No insurance
information for these subjects is available
to identify the subset of individuals who
participated in Medicare Part D, nor is in-
formation available about the subjects’
participation in speciﬁc formulary pro-
grams.
Medication data were collected dur-
ing an in-home visit; concurrence of
these medication lists with prescribed
medications in medical records was not
conﬁrmed. Medication adherence was ex-
amined using a validated self-reported
measure but was not veriﬁed by pill
counts, reﬁll data, or data from electron-
ically enabled medication bottles/caps.
Despite these limitations, this study pro-
vided important data about the growth of
access to generic antihypertensive medi-
cations and patterns of BP control
during a critical time period of changing
health policies in a large population of
African American and white diabetic
hypertensive subjects from across the
U.S.
In conclusion, among a national sam-
ple of African American and white subjects
with diabetes and hypertension, BP control
has improved; however, it remains inade-
quate relative to published guidelines, and
racial disparities in control persist. More-
over, although generically available antihy-
pertensive medications have increased, this
does not seem to be independently associ-
ated with patterns of improved BP control.
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